Carbocisteine or Hypertonic Saline for Acute Respiratory Failure.

Summary

In a 2×2 factorial multicenter RCT (n=1956) of ventilated ICU patients with acute respiratory failure, neither carbocisteine nor nebulized hypertonic saline reduced duration of mechanical ventilation. Carbocisteine increased clinically important upper GI bleeding, and hypertonic saline increased bronchoconstriction and hypoxemia during nebulization.

Key Findings

• No reduction in mechanical ventilation duration with carbocisteine (aHR 0.96) or HTS (aHR 1.00) versus respective controls.
• Carbocisteine increased clinically important upper GI bleeding (RR 6.51; P=0.01).
• HTS increased bronchoconstriction requiring bronchodilators (RR 5.73; P=0.001) and hypoxemia during nebulization (RR 13.29; P<0.001).
• No interaction between treatments in the factorial design (HR 1.01; P=0.91).

Clinical Implications

Routine use of carbocisteine or hypertonic saline for secretion management in ventilated ARF should be avoided; focus on evidence-based airway clearance and ventilator strategies.

Limitations

• Open-label design may introduce performance bias, though primary endpoint is objective.
• Generalizability to non-ventilated populations or different dosing regimens is uncertain.

Future Directions

Identify patient subsets (if any) who might benefit from targeted secretion management and evaluate alternative, safer airway clearance approaches.